Julian Upton

Pharma and healthcare are among the many areas being viewed with increasing attention inside and outside Greece, following the victory in the country’s elections of the radical left-wing, anti-austerity Syriza party.

Pharm Exec’s annual report highlights the key scientific, commercial, and reputational trends shaping the industry in the year ahead.

When he left school, Ian Harris wanted a career in brewing. He enrolled on a biochemistry degree with the intention of going on to study a master’s in brewing at Heriot-Watt University in Edinburgh, UK

The European Medicines Agency (EMA) has released a consultation on good genomics biomarker practices.

The UK government pledged late last year that it would double funding for dementia research by 2025 (from £66m [US$112m] in 2015 to £122m [US$207m]), but today Prime Minister David Cameron spoke on the subject again in light of expert warnings that little progress is being made.

They say the road to hell is paved with good intentions.

Innovation as a consideration of value-based pricing decisions will be conspicuous by its absence in future NICE decisions.

Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.

Approximately $12.7 billion has been invested in Latin America’s (LATAM’s) pharmaceutical market through mergers and acquisitions (M&As) in recent years.

For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive - muddling through is so yesterday.

European Union (EU) regulators today reached agreement on the much-vaunted Clinical Trials Regulation. The regulation harmonizes the rules for the conduct of clinical trials in the EU and the ‘acceptability’ of the resulting data, and places further safeguards on the safety of trial subjects.

The global Parkinson’s Disease market will decline from $3.4 billion in 2012 to $2.9 billion by 2019 (a negative Compound Annual Growth Rate of 2.3%), according to a new report by GBI Research (New York, NY).

FDA’s push for abuse-resistant opioid formulations will disrupt the pain market, say analysts Frost & Sullivan.

The number of drugs developed in Turku, Finland, and granted marketing authorizations this year now stands at three, with a fourth expected to follow.

In a bid to improve transparency in 2014, the European Medical Agency’s December Management Board Meeting cleared the way for the publication of the agendas and minutes of the Agency’s Committee for Medicinal Products for Human Use (CHMP), Committee for Medicinal Products for Veterinary Use (CVMP) and Committee for Advanced Therapies (CAT).

Compared to other manufacturing and technology industries, the bio/pharmaceutical industry has one of the longest product development timelines.

Another temporary casualty of the US government shutdown is the negotiation process surrounding the US and Europe’s free trade agreement.

Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.

Takeda's new $96 million plant in Russia is further proof of its expansive efforts to catch up in the BRIC countries. That is, the BRIC countries minus India. Chief Commercial Office Dr Frank Morich explains.

Industry is finding it harder to secure market access and payer uptake for new products. Innovative contracting may offer a solution. But is it working? Andrea Sobrio reports.

It’s an unusual sight in the UK - a television commercial for a Big Pharma company. But among the cultural and commercial innovations being attributed to the London Olympic Games is GSK’s first UK consumer-facing corporate brand campaign, showcasing its anti-doping operations.

UK pharma and biopharma was quick to respond positively to the Chancellor of the Exchequer’s annual Budget speech last week, despite some industry disappointment at a fiscal program widely derided as safe, neutral, and, in Andrew Goodwin of Ernst & Young’s words, “one of the most predictable” of recent times.

A recent global CEO report reveals that 51% of pharma CEOs think it has become more difficult to hire workers within the sector, outweighing the same problem in all other industries surveyed.

Of the 399 senior executives in the life sciences industry surveyed by the Economist Intelligence Unit (EIU) recently, 64% of respondents said that demonstrating value is a key challenge facing their business. The major issue, most agree, is that stakeholders have different perceptions of what value is.

December 01